Monte Rosa Therapeutics, Inc. 8-K

What Happened

• Monte Rosa Therapeutics, Inc. (GLUE) filed an 8-K on June 11, 2026 reporting the results of its 2026 Annual Meeting of Stockholders. The record date was April 16, 2026, with 84,382,573 shares of common stock outstanding.
• Stockholders elected three Class II directors — Andrew Schiff, M.D.; Chandra P. Leo, M.D.; and Anthony Manning, Ph.D. — each for a three-year term expiring at the 2029 annual meeting. The company also ratified Deloitte & Touche LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Details

• Record date and shares outstanding: 84,382,573 shares as of April 16, 2026.
• Director election vote totals:
  • Andrew Schiff, M.D.: For 71,409,008; Withheld 741,197; Broker non-votes 3,128,885.
  • Chandra P. Leo, M.D.: For 71,469,933; Withheld 680,272; Broker non-votes 3,128,885.
  • Anthony Manning, Ph.D.: For 56,995,916; Withheld 15,154,289; Broker non-votes 3,128,885.
• Auditor ratification vote: Deloitte & Touche LLP ratified — For 75,171,524; Against 57,950; Abstain 49,616; Non-votes 0.
• No other matters were submitted or voted on at the Annual Meeting.

Why It Matters

• Board composition and governance: Election of the three directors and their three-year terms (through 2029) affect oversight and strategic direction, which investors monitor for leadership stability.
• Audit oversight: Ratification of Deloitte & Touche LLP confirms continuity in external auditing for FY 2026, relevant to financial reporting and investor confidence.
• Vote details show strong support for two nominees and a larger withheld vote for Anthony Manning, which may be of interest to shareholders tracking board-level voting dynamics.